research use only
Cat.No.S3114
|
In vitro |
Water : 350 mg/mL (超声加热十分钟)
DMSO
: 35 mg/mL
(198.72 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 176.12 | Formula | C6H8O6 |
Storage (From the date of receipt) | 3 years -20°C powder (seal) |
|---|---|---|---|---|---|
| CAS No. | 50-81-7 | Download SDF | Storage of Stock Solutions | Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt. | |
| Synonyms | L-Ascorbic acid | SMILES | C(C(C1C(=C(C(=O)O1)O)O)O)O | ||
Read more about storage stability CAS number SMILES
| In vitro |
Ascorbate when combined with copper rapidly reduces the viscosity of DNA solutions and has exhibited some carcinostatic effects on transplanted sarcoma 180 tumours in mice. Exposure of HL-60 cells to increasing concentrations of H2O2 results in dose-dependent intracellular accumulation of peroxides, which is accompanied by a decrease in intracellular ascorbic acid and an increase in apoptosis. This compound loading also provides strong protection from apoptosis associated with serum- and glucose-free culture of HL-60 cells. This chemical is found to protect GSH-depleted HL-60 cells in a dose-dependent manner. It inhibits the formation of ROS in both normal and GSH-depleted cells. Ascorbate (1 mM) generates 161 mM H2O2 in Dulbecco's modified Eagle's medium and induces apoptosis in 50% of HL60 cells, whereas in RPMI 1640 only 83 mM H2O2 is produced and no apoptosis is detected. |
|---|---|
| In vivo |
Treatment of rats with Vitamin C 10 min prior to the cisplatin inhibits cisplatin-mediated damage. The enhanced serum creatinine levels which are indicative of renal injury shows a significant reduction with the three doses of this compound tested. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-06-26)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06068543 | SUSPENDED | Frailty; Inflammation |
University of Rochester |
2024-10-25 | PHASE2 |
| NCT07765667 | NOT_YET_RECRUITING | Rectal Adenocarcinoma; High-Risk Cancer; MSS |
Sixth Affiliated Hospital, Sun Yat-sen University |
2026-09-01 | PHASE2 |
| NCT06968936 | RECRUITING | Anemia; Iron Deficiencies; Cardiac Surgery |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-03-27 | |
| NCT06009744 | RECRUITING | Enterocutaneous Fistulas |
Hospital Juarez de Mexico |
2023-08 | |
| NCT04150042 | RECRUITING | Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Breast Cancer Metastatic; Breast Cancer Stage IV; Pancreatic Cancer Stage IV; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Adenocarcinoma of the Breast; PALB2 Gene Mutation; Pancreas Cancer, Metastatic; Pancreas Cancer, Recurrent; Pancreas Cancer; Stage IV Pancreatic Cancer; Stage 4 Pancreatic Cancer |
General Oncology, Inc. |
2021-01-13 | PHASE1 |
| NCT07197749 | NOT_YET_RECRUITING | Graft-versus-host-disease (GVHD); Gastrointestinal |
Baylor College of Medicine |
2026-11 | EARLY_PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.